A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
NCT ID: NCT00412958
Last Updated: 2014-12-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
125 participants
INTERVENTIONAL
2006-12-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ocriplasmin 25µg
25µg of ocriplasmin intravitreal injection
Ocriplasmin 25µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
Ocriplasmin 75µg
75µg of ocriplasmin intravitreal injection
Ocriplasmin 75µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
Ocriplasmin 125µg
125µg of ocriplasmin intravitreal injection
Ocriplasmin 125µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
Placebo
Intravitreal injection of placebo
Placebo
Intravitreal injection of placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ocriplasmin 25µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
Ocriplasmin 75µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
Ocriplasmin 125µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
Placebo
Intravitreal injection of placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Vitreous hemorrhage
* Certain vitreoretinal conditions including proliferative disease, rhegmatogenous retinal detachment, and proliferative vitreoretinopathy (PVR)
* Have had a vitrectomy in the study eye at any time
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ThromboGenics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Centers, P.C.
Tucson, Arizona, United States
VMR Institute
Huntington Beach, California, United States
Jules Stein Eye Institute/UCLA
Los Angeles, California, United States
Retinal Consultants of San Diego
Poway, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
National Ophtlamic Research Institute
Fort Meyers, Florida, United States
Center for Retina and Macular Disease
Winter Haven, Florida, United States
Rush University Med. Ctr
Chicago, Illinois, United States
Mailing add: New England Eye Center - Tufts
Boston, Massachusetts, United States
Associated Retinal Consultants, P.C.
Royal Oak, Michigan, United States
Vitroretinal Surgery, PA
Minneapolis, Minnesota, United States
Retina Vitreous Centre, PA
New Brunswick, New Jersey, United States
Columbia University - Harkness Eye Institute
New York, New York, United States
Retina Vitreous Surgeons of Central NY
New York, New York, United States
Duke Eye Center
Durham, North Carolina, United States
Retina Association of Cleveland
Lakewood, Ohio, United States
Allegheny Ophthalmic & Orbital Associates, P.C.
Pittsburgh, Pennsylvania, United States
Vanderbilt Eye Institute
Nashville, Tennessee, United States
Vitreoretinal Consultants
Houston, Texas, United States
Valley Retina Institute, P.A.
McAllen, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TG-MV-003
Identifier Type: -
Identifier Source: org_study_id